AstraZeneca plc (NYSE:AZN) – Analysts at Jefferies Group decreased their FY2018 earnings per share (EPS) estimates for AstraZeneca in a research note issued on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will earn $1.78 per share for the year, down from their prior estimate of $1.94. Jefferies Group also issued estimates for AstraZeneca’s FY2019 earnings at $1.88 EPS, FY2020 earnings at $2.19 EPS, FY2021 earnings at $2.68 EPS and FY2022 earnings at $3.21 EPS.

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. AstraZeneca’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.32 EPS.

Other analysts also recently issued research reports about the stock. BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Wednesday, November 15th. Citigroup upgraded shares of AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Sanford C. Bernstein reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, September 22nd. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, Cowen reiterated a “hold” rating and issued a $37.00 price objective on shares of AstraZeneca in a report on Tuesday, October 17th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $34.20.

AstraZeneca (AZN) traded up $0.09 during mid-day trading on Wednesday, reaching $35.08. 2,844,663 shares of the company’s stock were exchanged, compared to its average volume of 3,329,873. The firm has a market cap of $88,380.00, a P/E ratio of 25.06, a price-to-earnings-growth ratio of 3.42 and a beta of 0.76. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. AstraZeneca has a 12 month low of $26.51 and a 12 month high of $35.92.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can increased its holdings in shares of AstraZeneca by 243.4% during the 4th quarter. Bank of Montreal Can now owns 415,126 shares of the company’s stock worth $14,404,000 after buying an additional 294,246 shares during the last quarter. Clean Yield Group purchased a new position in shares of AstraZeneca during the 4th quarter worth approximately $205,000. Private Trust Co. NA purchased a new position in shares of AstraZeneca during the 4th quarter worth approximately $310,000. BLB&B Advisors LLC boosted its position in shares of AstraZeneca by 133.8% during the 4th quarter. BLB&B Advisors LLC now owns 54,849 shares of the company’s stock worth $1,903,000 after purchasing an additional 31,388 shares during the period. Finally, Atria Investments LLC boosted its position in shares of AstraZeneca by 26.3% during the 4th quarter. Atria Investments LLC now owns 33,495 shares of the company’s stock worth $1,162,000 after purchasing an additional 6,979 shares during the period. Institutional investors and hedge funds own 14.75% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “FY2018 EPS Estimates for AstraZeneca plc Decreased by Analyst (AZN)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/01/17/fy2018-eps-estimates-for-astrazeneca-plc-decreased-by-analyst-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.